Eli Lilly has announced plans to acquire Merida Biosciences, a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The… Read More
Cancer Research UK is set to invest £17 million ($23 million) and create up to 100 new jobs in a boost to the charity’s Manchester Institute. The Cancer Research UK Manchester Institute will receive an additional £6 million ($8 million) on top of the original £11 million… Read More
Jeff Fischer, MBA, president of Longhorn Vaccines and Diagnostics, examines how upstream activations in the gut microbiome can be utilised to tackle therapeutic targets. The microbiome has become a catch‑all explanation for everything from obesity to depression, but it can obscure a simpler and more actionable idea: that living microbes matter, but what they shed matters too. Every… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More
News round-up for 9 – 13 March February by Bruno Quinney, Content Team at DDW. This week, research on the brain has proved a popular theme, unlocking insights into Alzheimer’s, dementia and cancer. Elsewhere, a genetic target could provide new routes to breast cancer treatment. The top stories: … Read More
Mary Brunkow PhD is Senior Program Manager at the Institute for Systems Biology in Seattle in the US. She was one of three co-winners of the 2025 Nobel Prize in Physiology or Medicine for the discovery of regulatory T cells (Tregs). She shares her career highlights and some word of wisdom with Diana Turner. DT: What… Read More
Biotechnology company TECregen has appointed Dr Klaas Zuideveld as Chief Executive Officer. Zuideveld will lead the company’s strategy and execution as the company advances its thymopoietic biologics designed to rejuvenate thymic epithelial cells (TECs), restore immune function, and strengthen immune resilience. Zuideveld arrives with experience across large pharmaceutical companies and biotech, spanning translational strategy,… Read More
Biotechnology company Apogee Therapeutics has announced positive Phase I data for its antibody APG333. APG333, a novel half-life extended TSLP antibody, has been developed for inflammatory and immunology (I&I) markets. In the double-blind, placebo-controlled, first-in-human Phase I clinical trial, APG333 was well tolerated across all cohorts of… Read More
This eBook highlights recent examples of how cryo-EM and structural insights are being used across various therapeutic modalities to advance drug discovery pipelines. Structure-based drugs have two times the rate of clinical success at 50% of preclinical time and cost. Download this eBook to see the impact of cryo-EM on:… Read More
Biotechnology company Star Therapeutics has announced its $125 million Series D financing round was oversubscribed and will now initiate a clinical trial of its von Willebrand disease (VWD) therapy. The financing round was co-led by Sanofi Ventures and Viking Global Investors, with participation from both… Read More
What if we’re finally moving beyond managing autoimmune diseases and toward slowing their progression? That’s the promise behind Immunic Therapeutics’ recent long-term data on vidofludimus calcium (IMU‑838. Dr Daniel Vitt, CEO of Immunic, discusses these results and insights with DDW’s Megan Thomas. MT: Can you unpack what the sustained neuroprotective… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Professor Jonathan… Read More
This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More
Sanofi and Dren Bio, a clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that… Read More
Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch. OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan… Read More
Storm Therapeutics has presented promising data from its Phase I clinical study evaluating its METTL3 RNA methyltransferase inhibitor, STC-15, at the Society of Immunotherapy for Cancer (SITC) 39)th Annual Meeting, held in Houston, US, from 6-10 November 2024. The Phase I clinical study… Read More
